What You Should Know:
– Basil Systems, a provider of an AI-powered product lifecycle intelligence platform tailored for the life sciences industry, announced it has raised a total of $11.5M in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital.
– The infusion of capital is earmarked for significant expansion efforts, including enhancing its enterprise BasilIntel SaaS platform, deepening product capabilities, and accelerating the adoption of data-driven insights across the pharmaceutical and medical device sectors.
AI-Powered Intelligence Platform for Life Sciences
Life sciences companies frequently grapple with mission-critical operations hampered by outdated tools, siloed information, and manual processes. This fragmentation often leads to delays and risks in crucial areas like regulatory submissions, clinical trial planning, post-market surveillance, and competitive analysis, where timely, clear insights are paramount.
Basil Systems directly addresses these challenges by providing real-time, AI-driven intelligence. The company utilizes proprietary machine learning algorithms to automatically ingest, structure, and unify vast amounts of scattered data into a single, accessible source of truth. This approach empowers life sciences teams to make faster, more informed decisions, improve collaboration, and mitigate risks throughout the product lifecycle.
At the core of its offering is BasilLink, described as the largest indexed dataset in the life sciences industry, encompassing over 600 million continuously updated records. This extensive dataset includes regulatory filings, global drug labels, clinical trial data, adverse event reports, regulatory guidance, recalls, citations, inspection reports, and more.
The BasilIntel platform allows users to query this complex data landscape and receive answers in seconds through a natural language interface. For instance, users can quickly identify materials frequently linked to specific medical device failures or compare drug label changes across therapies for distinct patient groups. The platform also offers API connectivity and is built on enterprise-grade infrastructure capable of supporting millions of users concurrently.
Expanding Data Coverage
With the new funding, Basil Systems plans to further expand its data coverage within BasilLink, onboard additional enterprise clients, and enhance the rollout of AI and machine learning features to automate complex, high-stakes workflows. The company also intends to extend its platform’s support to adjacent players within the life sciences ecosystem, including drug and device manufacturers, suppliers, clinical research organizations (CROs), and regulatory agencies.
“Basil Systems has built the most comprehensive, structured dataset in life sciences, with over 600 million records spanning regulatory filings, clinical trials, post-market events, drug labels, and more,” said Anthony Cirurgiao, CEO and Founder, Basil Systems. “Our AI-powered platform transforms that data into real-time answers for the strategic questions that drive product success. We’re not just accelerating workflows and decision making, but creating a new standard for how life sciences companies make critical decisions across innovation, regulatory, safety and commercialization.”
